Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906

Autor:	Sonali M. Smith, Jeffrey L. Johnson, Donna Niedzwiecki, J. Paul Eder, George Canellos, Bruce D. Cheson, Nancy L. Bartlett, null for the Cancer and Leukemia Group B
Rok vydání:	2006
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty medicine.drug_class Phases of clinical research Aggressive lymphoma Disease-Free Survival Recurrence Internal medicine medicine Humans Doxorubicin Enzyme Inhibitors Aged Salvage Therapy biology business.industry Lymphoma Non-Hodgkin Topoisomerase Remission Induction Hematology Middle Aged medicine.disease Burkitt Lymphoma Lymphoma Non-Hodgkin's lymphoma Surgery biology.protein Female Topotecan Topoisomerase I Inhibitors business Topoisomerase inhibitor medicine.drug
Zdroj:	Leukemia & Lymphoma. 47:1511-1517
ISSN:	1029-2403 1042-8194
DOI:	10.1080/10428190600581385
Popis:	Topoisomerase enzymes are critical components of genomic replication and function to minimize torsional stress on DNA. Sequential administration of a topoisomerase II inhibitor followed by a topoisomerase I inhibitor is potentially synergistic due to increased target enzyme levels. Patients with relapsed or refractory aggressive non-Hodgkin's lymphomas (NHL) were eligible for this phase II study of doxorubicin 25 mg/m2 intravenous (IV) on day 1 and topotecan 1.75 mg/m2/day IV on days 3 - 5, every 21 days. The trial objectives included the overall response rate, progression-free survival, and toxicity. Twenty-six patients were enrolled and 25 patients are assessable for toxicity and response. The median age was 58 (range 23 - 74) years. The patients had received a median of two (range one to five) prior regimens, including five patients with a prior stem cell transplant. Five patients (20%, 95% confidence interval 0.07, 0.42) responded with two (8%) complete remissions and three (12%) partial remissions; an additional four (16%) patients had stable disease. Both patients achieving a complete remission had Burkitt's lymphoma. There were no treatment-related deaths. In conclusion, the combination of doxorubicin and topotecan is well tolerated and has modest activity in relapsed/refractory NHL, with occasional patients having a prolonged remission. The activity in Burkitt's lymphoma should be investigated further.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a1f7103aa68f4d2c47a09009df5bb47 https://doi.org/10.1080/10428190600581385 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.